Logo image of BME

BLACKROCK HEALTH SCIENCES (BME) Stock Price, Quote, News and Overview

NYSE:BME - New York Stock Exchange, Inc. - US09250W1071 - Currency: USD

36.4  +0.29 (+0.8%)

Fundamental Rating

2

Overall BME gets a fundamental rating of 2 out of 10. We evaluated BME against 0 industry peers in the Unkown industry. BME has a bad profitability rating. Also its financial health evaluation is rather negative. BME is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BME had positive earnings in the past year.
BME had a positive operating cash flow in the past year.
BME had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BME reported negative operating cash flow in multiple years.
BME Yearly Net Income VS EBIT VS OCF VS FCFBME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA 4.36%
ROE 4.4%
ROIC 0.13%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
BME Yearly ROA, ROE, ROICBME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15

1.3 Margins

BME's Profit Margin has declined in the last couple of years.
In the last couple of years the Operating Margin of BME has remained more or less at the same level.
Industry RankSector Rank
OM 12.29%
PM (TTM) 317.04%
GM 100%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
BME Yearly Profit, Operating, Gross MarginsBME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

More info and screens

3

2. Health

2.1 Basic Checks

BME has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BME has been increased compared to 5 years ago.
The debt/assets ratio for BME is higher compared to a year ago.
BME Yearly Shares OutstandingBME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BME Yearly Total Debt VS Total AssetsBME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

BME has an Altman-Z score of 66.46. This indicates that BME is financially healthy and has little risk of bankruptcy at the moment.
The Debt to FCF ratio of BME is 0.00, which is an excellent value as it means it would take BME, only 0.00 years of fcf income to pay off all of its debts.
A Debt/Equity ratio of 0.00 indicates that BME is not too dependend on debt financing.
Although BME does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 66.46
ROIC/WACCN/A
WACCN/A
BME Yearly LT Debt VS Equity VS FCFBME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.29 indicates that BME may have some problems paying its short term obligations.
A Quick Ratio of 0.29 indicates that BME may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
BME Yearly Current Assets VS Current LiabilitesBME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

BME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.59%, which is quite good.
Measured over the past years, BME shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.80% on average per year.
BME shows a decrease in Revenue. In the last year, the revenue decreased by -7.64%.
Measured over the past years, BME shows a quite strong growth in Revenue. The Revenue has been growing by 8.91% on average per year.
EPS 1Y (TTM)12.59%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-372.58%
Revenue 1Y (TTM)-7.64%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-10.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BME Yearly Revenue VS EstimatesBME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BME is valuated rather expensively with a Price/Earnings ratio of 22.61.
BME is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.52, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.61
Fwd PE N/A
BME Price Earnings VS Forward Price EarningsBME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 7.13
EV/EBITDA N/A
BME Per share dataBME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 7.97%, BME is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.38, BME pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.97%

5.2 History

The dividend of BME has a limited annual growth rate of 3.39%.
BME has paid a dividend for at least 10 years, which is a reliable track record.
BME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)3.39%
Div Incr Years1
Div Non Decr Years10
BME Yearly Dividends per shareBME Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

BME pays out 150.00% of its income as dividend. This is not a sustainable payout ratio.
BME's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP150%
EPS Next 2YN/A
EPS Next 3YN/A
BME Yearly Income VS Free CF VS DividendBME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M
BME Dividend Payout.BME Dividend Payout, showing the Payout Ratio.BME Dividend Payout.PayoutRetained Earnings

More info and screens

BLACKROCK HEALTH SCIENCES

NYSE:BME (6/6/2025, 8:04:00 PM)

36.4

+0.29 (+0.8%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners22.44%
Inst Owner Change-11.54%
Ins Owners0%
Ins Owner Change0%
Market Cap470.29M
Analysts0
Price TargetN/A
Short Float %0.14%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield 7.97%
Yearly Dividend2.67
Dividend Growth(5Y)3.39%
DP150%
Div Incr Years1
Div Non Decr Years10
Ex-Date06-13 2025-06-13 (0.2621)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 22.61
Fwd PE N/A
P/S 62.13
P/FCF 7.13
P/OCF 7.13
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)1.61
EY4.42%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)5.11
FCFY14.03%
OCF(TTM)5.11
OCFY14.03%
SpS0.59
BVpS42.24
TBVpS42.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.36%
ROE 4.4%
ROCE 0.17%
ROIC 0.13%
ROICexc 0.13%
ROICexgc 0.13%
OM 12.29%
PM (TTM) 317.04%
GM 100%
FCFM 871.86%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
ROICexc(3y)0.2%
ROICexc(5y)0.12%
ROICexgc(3y)0.2%
ROICexgc(5y)0.12%
ROCE(3y)0.25%
ROCE(5y)0.16%
ROICexcg growth 3Y199.74%
ROICexcg growth 5Y4.01%
ROICexc growth 3Y199.74%
ROICexc growth 5Y4.01%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 275%
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z 66.46
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.59%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-372.58%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.64%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-10.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.5%
EBIT growth 3Y185.41%
EBIT growth 5Y8.1%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y106.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.25%
OCF growth 3YN/A
OCF growth 5YN/A